Lung cancer drug repurposed in fight against Hard-to-Treat breast and stomach cancers
NCT ID NCT03620643
Summary
This study tested whether a drug called crizotinib, used for some lung cancers, could help control advanced lobular breast cancer and certain other hard-to-treat cancers. For breast cancer patients, it was combined with a hormone-blocking drug called fulvestrant. The main goal was to see if this combination could shrink tumors and was safe for the 33 participants who had already tried other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
-
Guys and St Thomas NHS Foundation Trust
London, United Kingdom
-
Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
University College London Hospital
London, United Kingdom
Conditions
Explore the condition pages connected to this study.